Abbott Laboratories
ABT
$123.62
-$1.05-0.84%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -7.59% | 34.26% | -85.64% | 460.69% | 26.42% |
| Total Depreciation and Amortization | 1.80% | 2.78% | -6.32% | 0.75% | -0.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -15.49% | -50.87% | -51.26% | 406.84% | -17.02% |
| Change in Net Operating Assets | 135.64% | 31.69% | 87.72% | -5,604.26% | 148.96% |
| Cash from Operations | 36.15% | 44.46% | -50.59% | 6.03% | 38.01% |
| Capital Expenditure | 1.20% | -3.72% | 32.78% | -29.50% | -4.32% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -83.33% | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -100.00% |
| Other Investing Activities | 288.00% | -457.14% | 109.59% | -284.21% | -148.10% |
| Cash from Investing | 21.48% | -23.83% | 45.73% | -45.79% | -31.13% |
| Total Debt Issued | -100.00% | 100.00% | 0.00% | 0.00% | -99.55% |
| Total Debt Repaid | -2,800.00% | 98.36% | -68.89% | -1,561.90% | 168.85% |
| Issuance of Common Stock | 97.14% | -87.80% | 1,048.00% | -72.83% | 607.69% |
| Repurchase of Common Stock | -4,983.33% | 97.86% | 11.11% | 58.06% | -24,933.33% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -0.19% | -0.29% | -7.10% | 0.21% | 0.10% |
| Other Financing Activities | 100.00% | -- | -- | -- | -- |
| Cash from Financing | -60.44% | 46.62% | -10.42% | -18.08% | -99.24% |
| Foreign Exchange rate Adjustments | -119.61% | 112.50% | 128.92% | -330.56% | 376.92% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 33.65% | 138.65% | -1,968.97% | -89.84% | -18.78% |